We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Leukocyte Biomarker Applied to Early Detection of Colon Cancer

By LabMedica International staff writers
Posted on 15 Feb 2011
Genetic material extracted from white blood cells can be used as biomarkers for the early detection of colon cancer. More...


The white blood cells, the monocytes, contain genetic material that when analyzed by a novel method, will enhance the monitoring of the development of the colon cancer in patients.

White blood cells play a significant role in the growth of tumors, the metastasis of cancer cells and the formation of blood vessels in and around tumors. In addition, they serve a crucial function in combating malignant cells. They form the core of the defense mechanism, which the body musters against cancer cells. The scientists will link changes in the genetic material of monocytes to the presence and progression of colon cancer. The advantage of this approach is that monocytes are easy to extract from the patient's blood sample.

Massimiliano Mazzone, PhD, who heads a laboratory at the Katholieke Universiteit Leuven (Leuven, Belgium), has just been awarded a substantial grant over a three year period to refine the technique. He has specialized in blood vessel formation in tumors. His most important discovery is the "phalanx cells,” highly streamlined cells on the inside of blood vessels that are needed for improved supply of oxygen. These more quiescent endothelial cell types in nongrowing vessels survive for many years and maintain lumen patency. These cells form a tightly aligned, orderly shaped, smooth layer with a typical cobblestone appearance, comparable to the "phalanx” formation of Greek Spartan soldiers.

The grant was awarded by The Fournier-Majoie Foundation for Innovation (FFMI; Brussels, Belgium). In close collaboration with oncology specialists at the University Hospital of Leuven (Leuven, Belgium), the grant recipients hope to go from the bench to the bedside in a very short time.

Related Links:
Katholieke Universiteit Leuven
The Fournier-Majoie Foundation
University Hospital of Leuven



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.